GLP1R and type 2 diabetes mellitus: Interestingly both the incretin mimetics (GLP-1 receptor agonists) and SGLT-2 inhibitors are considered the standard of care in preventing CV complications among T2D, due to their beneficial effects on reducing CV risk (62).